Protein aggregation and neurodegenerative disease

[1]  Christopher A Ross,et al.  The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. , 2004, Trends in cell biology.

[2]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[3]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[4]  M. Hayden,et al.  Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity , 2004, Journal of Biological Chemistry.

[5]  Ronald Wetzel,et al.  Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. , 2004, Molecular cell.

[6]  P. Pandolfi,et al.  SUMO Modification of Huntingtin and Huntington's Disease Pathology , 2004, Science.

[7]  A. Singleton,et al.  The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. , 2004, Human molecular genetics.

[8]  H. Paulson,et al.  For Personal Use. Only Reproduce with Permission the Lancet Publishing Group. Molecular Medicine for the Brain: Silencing of Disease Genes with Rna Interference , 2022 .

[9]  K. Chung,et al.  Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of α-synuclein , 2004 .

[10]  Thomas Scheibel,et al.  The elongation of yeast prion fibers involves separable steps of association and conversion. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Y. Cordeiro,et al.  Modulation of Prion Protein Oligomerization, Aggregation, and β-sheet Conversion by 4,4′-Dianilino-1,1′-binaphthyl-5,5′-sulfonate (bis-ANS)* , 2004, Journal of Biological Chemistry.

[12]  Takeshi Iwatsubo,et al.  Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective* , 2004, Journal of Biological Chemistry.

[13]  Michel Goedert,et al.  Tau protein and neurodegeneration. , 2004, Seminars in cell & developmental biology.

[14]  Christopher M Dobson,et al.  Principles of protein folding, misfolding and aggregation. , 2004, Seminars in cell & developmental biology.

[15]  N. Nukina,et al.  Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease , 2004, Nature Medicine.

[16]  Ying Xu,et al.  Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. , 2004, Journal of molecular biology.

[17]  D. Selkoe.  Folding proteins in fatal ways , 2003, Nature.

[18]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[19]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[20]  Leslie Michels Thompson,et al.  A Rapid Cellular FRET Assay of Polyglutamine Aggregation Identifies a Novel Inhibitor , 2003, Neuron.

[21]  J. Buxbaum.  Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? , 2003, Trends in biochemical sciences.

[22]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[23]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[24]  T. Iwatsubo.  Aggregation of α-synuclein in the pathogenesis of Parkinson’s disease , 2003, Journal of Neurology.

[25]  Ralf Langen,et al.  Structural Organization of α-Synuclein Fibrils Studied by Site-directed Spin Labeling* , 2003, Journal of Biological Chemistry.

[26]  M. Mattson,et al.  Good and Bad Amyloid Antibodies , 2003, Science.

[27]  R. Heinrikson,et al.  Human β-Secretase (BACE) and BACE Inhibitors , 2003 .

[28]  V. Uversky,et al.  Protein folding revisited. A polypeptide chain at the folding – misfolding – nonfolding cross-roads: which way to go? , 2003, Cellular and Molecular Life Sciences CMLS.

[29]  Haibin Xia,et al.  Allele-specific silencing of dominant disease genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Paulson,et al.  Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. , 2003, Current opinion in genetics & development.

[31]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[32]  Effat S. Emamian,et al.  Serine 776 of Ataxin-1 Is Critical for Polyglutamine-Induced Disease in SCA1 Transgenic Mice , 2003, Neuron.

[33]  D. Dash,et al.  Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: A molecular approach , 2003, Protein science : a publication of the Protein Society.

[34]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[35]  M. Hayden,et al.  Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity* , 2003, The Journal of Biological Chemistry.

[36]  F. Cohen,et al.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Tycko.  Insights into the amyloid folding problem from solid-state NMR. , 2003, Biochemistry.

[38]  Matthew P Frosch,et al.  The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.

[39]  Junying Yuan,et al.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders , 2003, Nature.

[40]  T. Dawson,et al.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease. , 2003, The Journal of clinical investigation.

[41]  Claudio Soto,et al.  Unfolding the role of protein misfolding in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[42]  C. Ross,et al.  Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. , 2003, Human molecular genetics.

[43]  C. Ross,et al.  Polyglutamine fibrillogenesis: The pathway unfolds , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Howard L. Weiner,et al.  Inflammation and therapeutic vaccination in CNS diseases , 2002, Nature.

[45]  R. Leapman,et al.  A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Lehrach,et al.  Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Chakrabartty,et al.  Oxidation-induced Misfolding and Aggregation of Superoxide Dismutase and Its Implications for Amyotrophic Lateral Sclerosis* , 2002, The Journal of Biological Chemistry.

[48]  M. Spillantini,et al.  Tau gene mutations: dissecting the pathogenesis of FTDP-17. , 2002, Trends in molecular medicine.

[49]  R. Wetzel,et al.  Mutational analysis of the structural organization of polyglutamine aggregates , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Citron.  Alzheimer's disease: treatments in discovery and development , 2002, Nature Neuroscience.

[51]  Christopher A. Ross,et al.  Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.

[52]  Ralf Langen,et al.  Structural and Dynamic Features of Alzheimer's Aβ Peptide in Amyloid Fibrils Studied by Site-directed Spin Labeling* , 2002, The Journal of Biological Chemistry.

[53]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[54]  S. Lindquist,et al.  Conversion of PrP to a Self-Perpetuating PrPSc-like Conformation in the Cytosol , 2002, Science.

[55]  S. Lindquist,et al.  Neurotoxicity and Neurodegeneration When PrP Accumulates in the Cytosol , 2002, Science.

[56]  K. Lindsten,et al.  Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. , 2002, Human molecular genetics.

[57]  Blair R. Leavitt,et al.  Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease , 2002, The Journal of Neuroscience.

[58]  R. Wetzel.  Ideas of order for amyloid fibril structure. , 2002, Structure.

[59]  K. Lindenberg,et al.  Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. , 2002, Molecular cell.

[60]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[61]  H. Cai,et al.  Genetically engineered mouse models of neurodegenerative diseases , 2002, Nature Neuroscience.

[62]  K. Fischbeck,et al.  Toxic Proteins in Neurodegenerative Disease , 2002, Science.

[63]  Ronald Wetzel,et al.  Amyloid-like features of polyglutamine aggregates and their assembly kinetics. , 2002, Biochemistry.

[64]  Christopher A. Ross,et al.  Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.

[65]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[66]  James C. Sacchettini,et al.  Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.

[67]  R. Wetzel,et al.  Conformational Abs recognizing a generic amyloid fibril epitope , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[68]  K. Winklhofer,et al.  Geldanamycin Restores a Defective Heat Shock Responsein Vivo * , 2001, The Journal of Biological Chemistry.

[69]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[70]  Piper Pw.  The Hsp90 chaperone as a promising drug target. , 2001 .

[71]  C. Ross,et al.  Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. , 2001, Trends in Molecular Medicine.

[72]  Jeffrey D. Rothstein,et al.  From charcot to lou gehrig: deciphering selective motor neuron death in als , 2001, Nature Reviews Neuroscience.

[73]  H. Zoghbi,et al.  SCA1 molecular genetics: a history of a 13 year collaboration against glutamines. , 2001, Human molecular genetics.

[74]  M. Wolfe,et al.  A Portrait of Alzheimer Secretases--New Features and Familiar Faces , 2001, Science.

[75]  R. Wetzel,et al.  Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. , 2001, Journal of molecular biology.

[76]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[77]  S. Prusiner,et al.  Shattuck lecture--neurodegenerative diseases and prions. , 2001, The New England journal of medicine.

[78]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[79]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[80]  S. Lindquist,et al.  Investigating protein conformation-based inheritance and disease in yeast. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[81]  J. Frydman,et al.  Molecular chaperones and the art of recognizing a lost cause , 2001, Nature Cell Biology.

[82]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[83]  P. Piper.  The Hsp90 chaperone as a promising drug target. , 2001, Current opinion in investigational drugs.

[84]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[85]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[86]  R. Leapman,et al.  Amyloid Fibril Formation by Aβ16-22, a Seven-Residue Fragment of the Alzheimer's β-Amyloid Peptide, and Structural Characterization by Solid State NMR† , 2000 .

[87]  D. F. Andrews,et al.  A one-hit model of cell death in inherited neuronal degenerations , 2000, Nature.

[88]  R A Houghten,et al.  Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library. , 2000, Journal of structural biology.

[89]  J. Dubochet,et al.  Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. , 2000, Journal of structural biology.

[90]  J. M. Smith,et al.  Direct visualisation of the beta-sheet structure of synthetic Alzheimer's amyloid. , 2000, Journal of molecular biology.

[91]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[92]  T. Benzinger,et al.  Two-Dimensional Structure of β-Amyloid(10−35) Fibrils† , 2000 .

[93]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[94]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[95]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[96]  D. Housman,et al.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[97]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[98]  C. Ross,et al.  Nuclear Targeting of Mutant Huntingtin Increases Toxicity , 1999, Molecular and Cellular Neuroscience.

[99]  Peter T. Lansbury,et al.  Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .

[100]  G P Bates,et al.  Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[102]  S. Hersch,et al.  Huntington aggregates may not predict neuronal death in Huntington's disease. , 1999, Annals of neurology.

[103]  M. MacDonald,et al.  Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.

[104]  T. Benzinger,et al.  Propagating structure of Alzheimer’s β-amyloid(10–35) is parallel β-sheet with residues in exact register , 1998 .

[105]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[106]  L. Bruijn,et al.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.

[107]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[108]  C. Blake,et al.  From the globular to the fibrous state: protein structure and structural conversion in amyloid formation , 1998, Quarterly Reviews of Biophysics.

[109]  S. W. Davies,et al.  Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.

[110]  P. Lansbury,et al.  Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. , 1997, Chemistry & biology.

[111]  P. Lansbury.  Structural Neurology: Are Seeds at the Root of Neuronal Degeneration? , 1997, Neuron.

[112]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[113]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[114]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[115]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[116]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[117]  D. Davies,et al.  The Interaction of an Epidermal Growth Factor/Transforming Growth Factor α Tail Chimera with the Human Epidermal Growth Factor Receptor Reveals Unexpected Complexities* , 1996, The Journal of Biological Chemistry.

[118]  J. Trojanowski,et al.  Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. , 1996, The American journal of pathology.

[119]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[120]  M. Hurle,et al.  Selective Inhibition of A Fibril Formation , 1996, The Journal of Biological Chemistry.

[121]  C A Ross,et al.  When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases , 1995, Neuron.

[122]  C. Glabe,et al.  Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. , 1994, The Journal of biological chemistry.

[123]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[124]  C. Sikström,et al.  Population Studies in Northern Sweden , 1988 .

[125]  D. Benson,et al.  Alzheimer's disease and Parkinson's disease , 1988, Neurology.

[126]  J. B. Martin,et al.  Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.

[127]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[128]  G. Glenner,et al.  X-RAY DIFFRACTION STUDIES ON AMYLOID FILAMENTS , 1968, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.